PRRT2 and Alzheimer disease: PKC hypofunction and therapeutic application of PKC activator were once suggested76,77, whereas the clinical trial of a PKC activator Bryostatin 1 for human AD patients was unsuccessful (https://clinicaltrials.gov/ct2/show/NCT02221947?term=PKC%2C+alzheimer&draw=2&rank=1).